**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 74796

**Manuscript Type:** MINIREVIEWS

**Pediatric acute viral hepatitis with atypical variants: Clinical dilemmas and natural history**

Sarma MS *et al*. Pediatric acute viral hepatitis with atypical variants

Moinak Sen Sarma, Aathira Ravindranath

**Moinak Sen Sarma,** Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Uttar Pradesh, India

**Aathira Ravindranath,** Division of Pediatric Gastroenterology, Apollo BGS Hospitals, Mysuru 570023, Karnataka, India

**Author contributions:** Sarma MS contributed the supervision and critical review of final draft of the manuscript; Ravindranath A contributed the literature search, data collection and writing first draft of manuscript; both authors wrote, read and approved the final manuscript.

**Corresponding author: Moinak Sen Sarma, MD, Associate Professor,** Department of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, Uttar Pradesh, India. moinaksen@gmail.com

**Received:** January 6, 2022

**Revised:** February 20, 2022

**Accepted: May 5, 2022**

**Published online:**

**Abstract**

Classical acute viral hepatitis (AVH) has an uncomplicated outcome. Acute liver failure has a grave prognosis. Atypical manifestations of AVH are a group of disorders that causes significant morbidity and dilemmas in children. These include prolonged cholestasis, relapsing hepatitis, ascitic form of AVH, late-onset hepatic failure (LOHF), intravascular hemolysis, and provoking an autoimmune trigger leading to autoimmune hepatitis. These entities cause significant liver dysfunction or worsening and are often difficult to differentiate from chronic liver disease (CLD). Ascitic form of AVH, LOHF, decompensated CLD and acute-on-chronic liver failure have significant overlapping features that need to be carefully dissected out. In many cases, only on long-term follow-up, these clinical entities can be separately identified. Intravascular hemolysis is usually caused by associated glucose-6-phosphate dehydrogenase deficiency. Rarely CLD such as Wilson disease and autoimmune hepatitis can also present with hemolysis in the initial presentation, which can mimic AVH with hemolysis. Identifying deviations from typical manifestations aid in avoiding unnecessary investigations, allowing focused therapy and alleviating anxiety.

**Key Words:** Viral; Hepatitis; Atypical; Cholestasis; Relapsing; Hemolysis; Ascites

Sarma MS, Ravindranath A. Pediatric acute viral hepatitis with atypical variants: Clinical dilemmas and natural history. *World J Hepatol* 2022; In press

**Core tip:** Acute viral hepatitis (AVH) in children can manifest with atypical features in about a quarter of children. The most common entities, such as prolonged cholestasis and relapsing hepatitis, cause liver dysfunction and are often confused with chronic liver diseases (CLDs). Similarly, ascitic form of AVH and late-onset hepatic failure are close differential diagnoses of acute-on-chronic liver failure and decompensated CLD. A combination of a thorough history, clinical findings, basic investigations and outcome on follow-up allows focused workup and management in atypical AVH.

**INTRODUCTION**

Ancient Sumerians considered the liver to be the seat of the soul and jaundice to be caused by the devil. From that era, we have come a long way in understanding hepatitis. Although the transmissible nature of hepatitis was known even in the Middle Ages, discovery of the Australia antigen and subsequently the other hepatotropic viruses formed the watershed in the history of acute viral hepatitis (AVH)[1]. While the majority of AVH has a benign self-limiting course with spontaneous resolution, acute liver failure (ALF) has a fulminant pattern with poor recovery of native liver. In between the two extremes of these phenotypes lies a major subgroup of complications that are collectively known as atypical manifestations of AVH (Figure 1). These entities have a variable outcome. They include complications such as prolonged cholestatic phase, relapsing hepatitis, ascitic variant of AVH, hematological involvement (immune thrombocytopenia, intravascular hemolysis, and aplastic anemia) and extrahepatic multisystemic issues (acute kidney injury, pancreatitis, Guillain-Barré syndrome, myocarditis, and myositis)[2]. In addition late-onset hepatic failure (LOHF), a debated entity closely mimics acute-on-chronic liver failure (ACLF). Due to the overlapping presentation, it is a challenging task to distinguish AVH from underlying chronic liver disease (CLD) (Figure 2). Of all the atypical features, this review is limited to the discussion of those uncommon features of AVH that are associated with liver dysfunction or worsening.

**EPIDEMIOLOGY**

The prevalence of AVH is variable but atypical manifestations are encountered in 14%-22% of children[3]. Etiology-specific prevalence is 30% in hepatitis A virus (HAV), 15% in hepatitis E virus (HEV) and 3% in hepatitis B virus (HBV) infections[3]. The wide range of prevalence is possibly due to the difference in definitions used to describe atypical features in the studies. Classical AVH begins with a prodrome that may include fever, nausea, vomiting, malaise followed by jaundice that resolves within the next 2-3 wk (Figure 3)[4]. Any deviation from this classical presentation is included under the umbrella of atypical features. Prolonged cholestasis is the most common atypical feature that is seen in 11%, AVH with ascites in 7%, intravascular hemolysis in 3% and relapsing jaundice in 2%[3].

***Prolonged cholestasis***

**Natural history:** In the natural history of typical AVH, the cholestatic phase lasts for a brief period (3-4 wk)[5]. Prolonged cholestasis is an atypical manifestation that is worrisome for the caregivers, a dilemma for physicians and troublesome for symptomatic patients. Deepening jaundice, pale stools, intractable pruritus, multivitamin deficiency features, fatigue, poor quality of life, school absenteeism and psychosocial difficulties predominate in this phase. In developing countries, the problem is compounded by self-imposed dietary restrictions that perpetuate malnutrition. In the initial description of cholestasis in patients with HAV infection, symptoms lasted for > 12 wk typically with serum bilirubin > 10 mg/dL and aminotransferases < 500 IU/L[6]. Liver biopsy in patients with cholestasis showed portal inflammation rich in plasma cells, centrilobular cholestasis, ductular proliferation and cholestatic rosettes. Periportal necrosis may impede the normal bile flow contributing to cholestasis[7]. In a pediatric study of prolonged cholestasis in HAV infection, the initial liver biopsies showed extensive periportal and centrilobular fibrosis similar to chronic hepatitis. A repeat biopsy 3 mo after resolution of cholestasis in the above cohort showed complete normalization and resolution of fibrosis[8]. Children who develop this deviation from the classical presentation are older (> 10 years) and more commonly have HAV (15%) as compared to HBV (1%), HEV (9%) and coinfections (11%). Cholestasis can last up to 6 mo and 10% can also have relapsing hepatitis. Jaundice to pruritus interval is usually 20 (15-30) d[3]. Figure 4 depicts the natural history of the prolonged cholestatic phase. It is postulated that HAV infection triggers polymorphisms in ATP binding cassette proteins that are involved in bile secretion[9]. It has also been observed that in prolonged cholestasis, the time taken for HAV RNA to become undetectable in the serum is 46-105 d as compared to 11-20 d in classical hepatitis[10]. These findings indirectly indicate that a complex interaction exists between genetic predisposition, immune response to HAV and prolongation of cholestasis.

**Differential diagnosis:** When a child presents for the first time with a long history of icterus (progressive or relapsing), pruritus or pale stools, the tendency would be to look for cholestatic chronic liver diseases. Intrahepatic causes of cholestasis include progressive familial intrahepatic cholestasis, sclerosing cholangitis, Alagille syndrome, cystic fibrosis, alpha-1-antitrypsin deficiency and infiltrative disorders. Extrahepatic causes of cholestasis are choledochal cyst, Caroli’s disease, sclerosing cholangitis, biliary stricture, biliary compression by lymph nodes or masses and portal cavernoma cholangiopathy[11]. Clues in the clinical presentation, extrahepatic manifestations, familial clustering, features of portal hypertension and radiology distinguish the above.

Mutations in *ATP8B1*, *ABCB11* and *TJP2* present as cholestasis from early infancy with persistently low or normal γ-glutamyl transpeptidase (GGT) levels and liver dysfunction[12]. Hence these disorders are rarely confused for AVH with prolonged cholestasis. Mutations in *ABCB4* gene that result in a dysfunctional multidrug-resistant protein (MDR)3 may have milder phenotypes that appear for the first time as cholestasis during AVH. These disorders have a significant family history, maternal antenatal cholestasis, recurrent cholestatic pattern, biliary (intrahepatic and gall bladder) calculi and persistently high GGT levels[13]. Liver biopsy would demonstrate periportal fibrosis and ductular proliferation with absence or faint staining of MDR3 protein in immunohistochemistry[14]. Benign recurrent intrahepatic cholestasis is a milder variant in all the above disorders that have recurrent bouts of cholestasis in the second decade without progressive liver disease[15]. These bouts may overlap with AVH. Genetic analysis should be sent if clinical suspicion is strong.

Alagille syndrome is an autosomal dominant disorder due to mutation in either *JAGGED1* or *NOTCH2* genes with incomplete penetrance and variable expressivity[16]. Hepatic involvement may range from asymptomatic elevation of transaminases to decompensated CLD. The majority will have cholestasis in early infancy which can progress or resolve. A small proportion may present for the first time with late-onset cholestasis up to the age of 10 years who may mimic prolonged cholestasis of AVH[17]. Characteristic facies along with positive family history, cardiac and skeletal abnormalities, will provide clues to the underlying disease. Liver biopsy showing paucity of interlobular bile ducts and/or positive mutation will confirm the diagnosis[18].

It is known that smooth muscle actin (SMA) and antinuclear (ANA) autoantibodies, may be incidentally detected during AVH due to autoimmune phenomena[19]. Those presenting with cholestasis may be mistaken as having autoimmune sclerosing cholangitis or overlap syndrome. In those with extrahepatic autoimmunity, features of portal hypertension and biliary changes on sonography should be worked up with magnetic resonance cholangiography and/or liver biopsy[20].

Drug-induced liver injury (DILI) often complicates a regular course of AVH. A variety of complications such as a surge in transaminases, liver failure and cholestasis may occur during this period. It is important to carefully elicit a concomitant drug intake, especially herbal and alternative medicines. Liver tonics and immune boosters are marketed widely in Asia and obtained over the counter with a myth of hastening the recovery of icterus[21]. Commonly used drugs that can cause cholestasis include antibiotics like amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole, erythromycin and tricyclic antidepressants.[22] Temporal correlation with drug intake and improvement upon withdrawal supports the diagnosis of drug-induced cholestasis. However, in cases of chronic cholestasis, improvement may not be evident even after drug withdrawal and may progress to CLD[23]. In Asian children with DILI, 39% of cases were accounted for by herbal medications and the rest by antitubercular drugs, antibiotics and antiepileptics. Twenty-seven percent had a cholestatic pattern and 22% had a mixed pattern of injury based on the R factor. Fourteen percent went on to develop chronic DILI. Non-hepatocellular injury pattern was one of the factors predicting poor outcomes[24].

In a setting of prolonged cholestasis in AVH, an extensive workup including liver biopsy is generally not required. It is prudent to wait and watch for the natural resolution to take place if the liver functions are improving over 3-4 mo. Detailed workup for chronic diseases is indicated if there are significant clues in presentation, static or worsening liver dysfunction.

**Treatment:** Although spontaneous resolution can be seen, sequential pharmacotherapy may be required in those with significant and debilitating cholestasis-related pruritus. Ursodeoxycholic acid could aid in the resolution of cholestasis in 80% of cases. It increases the hydrophilicity of bile, induces the activity of carrier proteins for increasing biliary secretion and has antiapoptotic activity[25]. Addition of rifampicin is required in 18% of cases. Rifampicin acts as an agonist of pregnane-X-receptor, which in turn mitigates bile acid toxicity. Cholestyramine, a bile acid sequestrant is required in 4% of cases[3]. In refractory cases, opioid antagonist (naltrexone) or selective serotonin reuptake inhibitor (sertraline) is used for severe pruritus[26]. The role of steroids in prolonged cholestasis of AVH is questionable. Few case series have shown a response of refractory pruritus to prednisolone (1 mg/kg/d) for 2 wk with tapering over 4-8 wk[27]. Multivitamin supplementation is prudent.

***Relapsing hepatitis***

**Natural history:** Relapsing hepatitis is seen in 2-4% of children with AVH in whom it typically presents as a biphasic illness or rarely polyphasic relapses[6,8]. In this entity, the second phase of hepatitis occurs after the resolution of the first phase and near-normalization of liver functions. The interval period between the two hepatitic phases may last for weeks to months[28]. The second or subsequent phases may be icteric or anicteric. There may be a recurrence of prodrome. The peaks of liver enzymes may be variable or similar to the first episode. The subsequent phase may be similar, less severe or more severe than the first episode. Rarely, the relapsed phase may culminate in ALF or complicate into a cholestatic phase[29]. Figure 5 depicts the natural history of relapsing hepatitis in AVH. Since liver function tests are measured at fixed time points of follow-up, anicteric relapses may often be missed. Hence the true prevalence of relapsing hepatitis remains undermined. During the relapses, HAV RNA can be detected in the serum and IgM HAV remains positive[11]. Relapse is postulated to result from incomplete elimination of HAV in the initial phase. Recent mouse model studies have shown that anti-HAV IgA immune complexes reach the liver from the enterocytes by enterohepatic circulation. The process is continuous until IgG response is initiated. In those with inefficient IgG response, recurrent seeding of anti-HAV IgA immune complex to the liver can cause relapsing hepatitis[30]. Treatment is supportive with close monitoring for progression to ALF.

**Differential diagnosis:** Relapsing jaundice is the presenting feature in 33% of children with autoimmune hepatitis that can last from 6 to 24 mo. Apart from icterus, presentations are fatigue, weight loss and anorexia. Absence of acute viral markers, presence of stigmata of CLD, decompensation or features of portal hypertension warrant workup for autoimmune hepatitis[31].

Sclerosing cholangitis can present with multiple relapses and spontaneous remissions. Magnetic resonance cholangiography and workup for underlying etiology confirm the diagnosis in the majority of cases. However, about 13% of cases of primary sclerosing cholangitis have exclusive small duct involvement that can be confirmed only by liver biopsy[32]. Children with extrahepatic biliary obstruction have a prominent history of recurrent fever, cholangitis and absence of prodrome that differentiates from relapsing viral hepatitis.

Children with ATP8B1 and ABCB11 disease present with recurrent jaundice in 8% and recurrent-persistent jaundice in 23% of cases. Pruritus is a universal feature in them[33]. Recurrent jaundice in ABCB4 disease is variable, dependent on the severity of mutation and often precipitated by drugs[34,35]. Dubin-Johnson syndrome is a rare disorder of bilirubin excretion due to mutations in *ABCC2* gene, with a characteristic black liver caused by lysosomal pigment accumulation. These patients can present with recurrent jaundice with elevated conjugated bilirubin from as early as 7 years of age[36]. Hemolytic disorders and Gilbert syndrome clinically present with recurrent jaundice; however, they have unconjugated hyperbilirubinemia[37]. These disorders have normal liver enzymes and synthetic functions.

***AVH with ascites***

**Natural history:** Ascites in children with AVH is present in 13% of cases; of which 38% are clinically detectable and have high serum ascites albumin gradient (> 1.1). Eleven percent have evidence of ascitic fluid infection (AFI). Associated pedal edema is present in 33% of cases and pleural effusion (hepatic hydrothorax) in 44%[38]. Children who develop ascites in AVH are younger, with lower serum albumin, lower total protein and higher prothrombin time, signifying greater liver dysfunction than those with uncomplicated AVH. Features of portal hypertension (esophagogastric varices, portal hypertensive gastropathy, dilated portal vein, and abdominal portosystemic collaterals) or chronicity (shrunken liver, nodular surface, irregular margins or differential lobe hypertrophy) are not seen. Diuretics are required in 44% of cases. Unlike CLD, the ascites responds rapidly and completely by 8 wk without any recurrence. The resolution is paralleled with complete improvement in liver function and normalization of liver size (appropriate for age)[38]. Figure 6 depicts the natural history of ascites in AVH. The mechanism of development of ascites was elegantly demonstrated in a study in which hepatic venous pressure gradient (HVPG) and liver histology were analyzed, which showed that liver cell dropout caused sinusoidal collapse that impeded intrahepatic blood flow resulting in portal hypertension. This finding was corroborated by the demonstration of higher HVPG (> 6mmHg) in those with ascites[39].

**Differential diagnosis:** Ascites in the setting of liver dysfunction needs to be carefully analyzed. In a given case, there may be significant overlap between various entities of diagnostic and therapeutic dilemmas. Differential diagnoses of ascitic form of AVH are decompensated CLD, acute on chronic liver failure (ACLF) and LOHF as summarized in Table 1. Decompensation in those with CLD is defined as ascites, encephalopathy and/or gastrointestinal bleeding. Among all admitted children with CLD, 40% have ascites[40,41]. Twenty eight percent of children with decompensated CLD have evidence of AFI[42]. According to the Asian Pacific Association for the Study of Liver Diseases (APASL), ACLF is defined as acute hepatic insult manifesting as jaundice (serum bilirubin > 5 mg/dL) and coagulopathy (INR > 1.5) complicated within 4 wk by clinically detectable ascites and/or hepatic encephalopathy in a patient with previously diagnosed or undiagnosed CLD[43]. Among the children with ACLF, 92% had ascites and 66% had hepatic encephalopathy. The majority of them presented for the first time with ACLF and CLD, and were silent until the precipitation of severe liver dysfunction. AVH was the precipitating factor in one-third of them, HAV and HEV in 35% each, HBV in 17% and Epstein-Barr virus in 11%[44]. Thus, in a child presenting with jaundice and ascites, features of portal hypertension and chronic liver disease ought to be looked for actively. Esophagogastroduodenoscopy, portal vein diameter (age-appropriate cut-off values), HVPG and liver biopsy are required in selected cases. Other supportive elements such as presence of growth failure, stigmata of CLD and their etiologies, family history of CLD, or past history of similar symptoms reinforce the suspicion of an underlying CLD.

**Treatment:** Restriction of dietary sodium to 2 mEq/kg/d, fluid restriction and diuretics form the mainstay of management of clinically significant ascites. Ascites in AVH rarely require aggressive management like large-volume paracentesis and albumin infusions. Diagnostic tapping of new-onset ascites in any liver disease is important for the presence of AFI. AFI needs to be treated as per the recommended antibiotic guidelines[45].

***LOHF***

**Natural history:** In the disease continuum of ALF, a subset of patients with liver dysfunction fall into the criteria where jaundice to encephalopathy interval ranges for a longer period commonly 5 to 12 wk.[46] This entity has been termed as sub-fulminant hepatic failure, sub-acute hepatic failure or LOHF. Other authors have re-defined the same entity differently in various studies with jaundice to encephalopathy interval ranging from 2 wk to 26 wk[47,48]. Most experts agree that the cut-off between jaundice and encephalopathy should be > 4 wk interval to define LOHF.[49] The definition of pediatric ALF lacks a discrete timeline thus making it difficult to recognize LOHF in children[50]. LOHF occupies a distinct position in the maze of severe liver dysfunction that is different from ALF and ACLF in terms of difference in its natural history and prognosis[51].

Of all the children with ALF, LOHF is seen in 8.3% with a median duration of illness of 53 d and an interval between jaundice and liver failure (ascites or encephalopathy) of 35 d. Ascites is the predominant sign of the failing liver seen in 94% and encephalopathy is present in 50% (advanced encephalopathy in 11%). Among all cases of LOHF, AVH is the most frequent etiology in nearly two-thirds with HAV being the most common which is also the predominant etiology of AVH (64%) as well as ALF (70%) in developing countries[6,52]. In contrast HBV is the predominant etiology in adults with LOHF (32-46%)[53]. Mortality is higher in children with indeterminate etiology, hepatic encephalopathy, renal failure, infection, coagulopathy and high pediatric end-stage liver disease (PELD) score. Thus, referral for liver transplantation should be considered earlier in this group of children with LOHF. PELD score > 32 can predict mortality or the need for liver transplantation with good sensitivity. Post-mortem liver biopsy shows multiacinar massive or submassive necrosis without any features of chronicity. One-fourth of children recover spontaneously with native liver, as late as 24 mo after the onset of illness and without any evidence of CLD on follow-up[54]. This is in contrast to adults who exhibit features of chronic hepatitis in LOHF at follow-up[51]. It is imperative to recognize that LOHF is not merely old wine in a new bottle but is a distinctive entity whose natural history is yet to be determined diligently in children.

**Differential diagnosis:** ACLF, decompensated CLD closely mimics LOHF. The absence of coagulopathy differentiates ascitic form of AVH from LOHF.

**Treatment:** Supportive treatment in lines of ALF management, maintenance of euglycemia, electrolytes, control of ascites and encephalopathy are required. Since they are at high risk of developing infections, a lower threshold has to be maintained for starting or changing antibiotics. Raised intracranial pressure is uncommon in LOHF thus, management of encephalopathy would be as per the guidelines for those with CLD[55].

***Intravascular hemolysis in liver disease***

**Natural history:** Intravascular hemolysis at presentation is encountered in 3% of children with AVH[3]. They have severe anemia, deep icterus and dark-colored urine akin to cola. Since the jaundice is accentuated, there is often a dilemma in interpretation of liver function tests and chances of overdiagnosing the condition as terminal liver disease. Liver functions show a high fraction of unconjugated bilirubin. Aspartate aminotransferase is higher than alanine aminotransferase. Lactate dehydrogenase levels is markedly elevated. Reticulocyte count is high and peripheral smear shows schistocytes and hemolytic cells. Intravascular hemolysis is further evident by demonstrating plasma hemoglobin and urine hemosiderin elevation. Underlying glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is often unveiled in an episode of AVH or by drugs like vitamin K. Among those with hemolysis, there is G-6-PD deficiency in 36%, direct Coomb’s test positive in 7%[3]. It is crucial to identify hemolysis early to avoid drugs that precipitate red blood cell destruction especially vitamin K which is universally administered in AVH and also to start appropriate fluid management to prevent pigment nephropathy[56]. G-6-PD levels may be falsely normal when measured during an acute episode of hemolysis due to relatively higher levels in new red blood cells. Hence, it has to be repeated after 3 mo to confirm G-6-PD deficiency, until then all contraindicated drugs have to be avoided. Figure 7 depicts the natural history of intravascular hemolysis associated with AVH.

**Differential diagnosis:** Hemolysis is associated with CLD in Wilson disease and autoimmune hepatitis. Acute hemolysis as the presenting feature would be there in 6.7% of cases of Wilson disease[57]. Acute release of copper from the necrosing liver cells is postulated to cause damage to the RBC membrane resulting in hemolysis, which is supported by finding very high serum and urine copper levels. Hemolysis is present in 22% of all children with Wilson disease and this proportion increases to 68% when considering those presenting as ALF[58]. Leipzig score which is used to diagnose Wilson disease in children gives weightage to Coomb’s negative hemolytic anemia in addition to low ceruloplasmin, high urinary copper, high liver copper, positive copper staining on hepatocytes, Kayser-Fleisher ring, neuropsychiatric symptoms, positive family history and mutation in ATP7B gene[59]. Acute hemolysis in Wilson disease is an emergency as it is an indication to start immediate plasmapheresis to remove excess serum copper and also list for liver transplantation[60]. Autoimmune hemolytic anemia in children with autoimmune hepatitis is encountered in 35% of children. Coomb’s test will be positive and needs to be treated with steroids and/or immunoglobulins[61].

**Treatment:** In acute intravascular hemolysis in the background of AVH, with a presumed diagnosis of G-6-PD deficiency all contraindicated drugs should be stopped. Hyper-hydration and diuretics to maintain urine output would protect from pigment nephropathy[62]. Simultaneous work-up for Wilson disease and autoimmune hepatitis ought to be done in select cases so that specific treatment is not delayed. In case of development of acute kidney injury, plasmapheresis and dialysis support may be required.

***Autoimmune trigger***

HAV infection itself can act as a trigger to uncover autoimmunity. In children with HAV, 63% have positive autoantibodies (60% ASMA and 3% ANA). LKM antibodies are usually not found in concomitant AVH[63]. The release of intracellular antigen during hepatocyte necrosis induces the antibody formation. The genes associated with the development of type 1 autoimmune hepatitis are located in HLA II DRB1 0301 Loci which are also reported to be present in those with persistent HAV infection. This may explain the precipitating role of HAV in autoimmune hepatitis[64]. Though autoantibodies have been demonstrated in children with HAV, the exact role of HAV in triggering AIH is not well studied in children.

***Systemic complications of AVH***

Other than the above atypical features, systemic complications of AVH include acute kidney injury, thrombocytopenia, acute pancreatitis, hemophagocytic lymphohistiocytosis, aplastic anemia and transverse myelitis[65].

**CONCLUSION**

Atypical presentations of AVH may have a myriad of presentations often mimicking an underlying CLD. Understanding the natural history of relapsing hepatitis, prolonged cholestasis, ascites and intravascular hemolysis in the setting of AVH aids in decision-making and avoiding unwarranted investigations that be may be unyielding. Invasive investigations and aggressive management must be carefully considered and indicated only when the suspicion is strong for an underlying CLD. LOHF is a distinct and aggressive variant of AVH that needs to be viewed in the lines of ALF.

**REFERENCES**

1 **Trepo C**. A brief history of hepatitis milestones. *Liver Int* 2014; **34** Suppl 1: 29-37 [PMID: 24373076 DOI: 10.1111/Liv.12409]

2 **Alam R**, Karim ASMB, Mazumder MW, Das SR, Benzamin M, Sonia ZF, Rahman SMH. Atypical manifestations of acute viral hepatitis A in children in Bangladesh: Are these really uncommon? *Indian J Gastroenterol* 2021; **40**: 470-476 [PMID: 34783989 DOI: 10.1007/s12664-021-01200-9]

3 **Singh SK**, Borkar V, Srivastava A, Mathias A, Yachha SK, Poddar U. Need for recognizing atypical manifestations of childhood sporadic acute viral hepatitis warranting differences in management. *Eur J Pediatr* 2019; **178**: 61-67 [PMID: 30269249 DOI: 10.1007/s00431-018-3262-3]

4 **Migueres M**, Lhomme S, Izopet J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. *Viruses* 2021; **13** [PMID: 34696330 DOI: 10.3390/v13101900]

5 **Jung YM**, Park SJ, Kim JS, Jang JH, Lee SH, Kim JW, Park YM, Hwang SG, Rim KS, Kang SK, Lee HS, Yun HS, Jee YM, Jeong SH. Atypical manifestations of hepatitis A infection: a prospective, multicenter study in Korea. *J Med Virol* 2010; **82**: 1318-1326 [PMID: 20572083 DOI: 10.1002/jmv.21822]

6 **Gordon SC**, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. *Ann Intern Med* 1984; **101**: 635-637 [PMID: 6486595 DOI: 10.7326/0003-4819-101-5-635]

7 **Sciot R**, Van Damme B, Desmet VJ. Cholestatic features in hepatitis A. *J Hepatol* 1986; **3**: 172-181 [PMID: 3025288 DOI: 10.1016/s0168-8278(86)80023-x]

8 **Samanta T**, Das AK, Ganguly S. Profile of hepatitis A infection with atypical manifestations in children. *Indian J Gastroenterol* 2010; **29**: 31-33 [PMID: 20373084 DOI: 10.1007/s12664-010-0006-3]

9 **Krawczyk M**, Grünhage F, Langhirt M, Bohle RM, Lammert F. Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. *Ann Hepatol* 2012; **11**: 710-714 [PMID: 22947535 DOI: 10.1016/S1665-2681(19)31448-6]

10 **Sagnelli E**, Coppola N, Marrocco C, Onofrio M, Scarano F, Marotta A, Scolastico C, Catuogno A, Salzillo A, Sagnelli C, Piccinino F, Filippini P. HAV replication in acute hepatitis with typical and atypical clinical course. *J Med Virol* 2003; **71**: 1-6 [PMID: 12858402 DOI: 10.1002/jmv.10455]

11 **Jagadisan B**, Srivastava A. Child with Jaundice and Pruritus: How to Evaluate? *Indian J Pediatr* 2016; **83**: 1311-1320 [PMID: 26932879 DOI: 10.1007/s12098-016-2058-6]

12 **Agarwal S**, Lal BB, Rawat D, Rastogi A, Bharathy KG, Alam S. Progressive Familial Intrahepatic Cholestasis (PFIC) in Indian Children: Clinical Spectrum and Outcome. *J Clin Exp Hepatol* 2016; **6**: 203-208 [PMID: 27746616 DOI: 10.1016/j.jceh.2016.05.003]

13 **Alam S**, Lal BB. Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies. *World J Hepatol* 2022; **14**: 98-118 [PMID: 35126842 DOI: 10.4254/wjh.v14.i1.98]

14 **Al-Hussaini A**, Lone K, Bashir MS, Alrashidi S, Fagih M, Alanazi A, AlYaseen S, Almayouf A, Alruwaithi M, Asery A. ATP8B1, ABCB11, and ABCB4 Genes Defects: Novel Mutations Associated with Cholestasis with Different Phenotypes and Outcomes. *J Pediatr* 2021; **236**: 113-123.e2 [PMID: 33915153 DOI: 10.1016/j.jpeds.2021.04.040]

15 **Halawi A**, Ibrahim N, Bitar R. Triggers of benign recurrent intrahepatic cholestasis and its pathophysiology: a review of literature. *Acta Gastroenterol Belg* 2021; **84**: 477-486 [PMID: 34599573 DOI: 10.51821/84.3.013]

16 **Yang Y**, Wang H. A novel JAG1 frameshift variant causing Alagille syndrome with incomplete penetrance. *Clin Biochem* 2022 [PMID: 35151641 DOI: 10.1016/j.clinbiochem.2022.02.004]

17 **Lykavieris P**, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. *Gut* 2001; **49**: 431-435 [PMID: 11511567 DOI: 10.1136/gut.49.3.431]

18 **Kamath BM**, Munoz PS, Bab N, Baker A, Chen Z, Spinner NB, Piccoli DA. A longitudinal study to identify laboratory predictors of liver disease outcome in Alagille syndrome. *J Pediatr Gastroenterol Nutr* 2010; **50**: 526-530 [PMID: 20421762 DOI: 10.1097/MPG.0b013e3181cea48d]

19 **Terziroli Beretta-Piccoli B**, Ripellino P, Gobbi C, Cerny A, Baserga A, Di Bartolomeo C, Bihl F, Deleonardi G, Melidona L, Grondona AG, Mieli-Vergani G, Vergani D, Muratori L; Swiss Autoimmune Hepatitis Cohort Study Group. Autoimmune liver disease serology in acute hepatitis E virus infection. *J Autoimmun* 2018; **94**: 1-6 [PMID: 30336842 DOI: 10.1016/j.jaut.2018.07.006]

20 **Kemme S**, Mack CL. Pediatric Autoimmune Liver Diseases: Autoimmune Hepatitis and Primary Sclerosing Cholangitis. *Pediatr Clin North Am* 2021; **68**: 1293-1307 [PMID: 34736590 DOI: 10.1016/j.pcl.2021.07.006]

21 **Verma S**, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. *Clin Gastroenterol Hepatol* 2007; **5**: 408-416 [PMID: 17222587 DOI: 10.1016/j.cgh.2006.10.014]

22 **Petrov PD**, Soluyanova P, Sánchez-Campos S, Castell JV, Jover R. Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. *Food Chem Toxicol* 2021; **158**: 112664 [PMID: 34767876 DOI: 10.1016/j.fct.2021.112664]

23 **Padda MS**, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. *Hepatology* 2011; **53**: 1377-1387 [PMID: 21480339 DOI: 10.1002/hep.24229]

24 **Kumar A**, Sood V, Khanna R, Verma SK, Mehra N, Rawat D, Alam S. Clinical Spectrum and Outcome of Pediatric Drug Induced Liver Injury. *Indian J Pediatr* 2018; **85**: 676-678 [PMID: 29247427 DOI: 10.1007/s12098-017-2570-3]

25 **Paumgartner G**, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. *Hepatology* 2002; **36**: 525-531 [PMID: 12198643 DOI: 10.1053/jhep.2002.36088]

26 **Kremer AE**, Bolier R, van Dijk R, Oude Elferink RP, Beuers U. Advances in pathogenesis and management of pruritus in cholestasis. *Dig Dis* 2014; **32**: 637-645 [PMID: 25034299 DOI: 10.1159/000360518]

27 **Kumar P,** Bhatia V. Prolonged cholestasis due to hepatitis A virus infection. *Indian Pediatr* 2011; **48**: 485-486

28 **Muñoz-Martínez SG**, Díaz-Hernández HA, Suárez-Flores D, Sánchez-Ávila JF, Gamboa-Domínguez A, García-Juárez I, Torre A. Atypical manifestations of hepatitis A virus infection. *Rev Gastroenterol Mex (Engl Ed)* 2018; **83**: 134-143 [PMID: 29685743 DOI: 10.1016/j.rgmx.2017.10.004]

29 **Webb GW**, Kelly S, Dalton HR. Hepatitis A and Hepatitis E: Clinical and Epidemiological Features, Diagnosis, Treatment, and Prevention. *Clin Microbiol Newsl* 2020; **42**: 171-179 [PMID: 33110280 DOI: 10.1016/j.clinmicnews.2020.10.001]

30 **Dotzauer A**, Heitmann A, Laue T, Kraemer L, Schwabe K, Paulmann D, Flehmig B, Vallbracht A. The role of immunoglobulin A in prolonged and relapsing hepatitis A virus infections. *J Gen Virol* 2012; **93**: 754-760 [PMID: 22170633 DOI: 10.1099/vir.0.038406-0]

31 **Gregorio GV**, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, Mieli-Vergani G. Autoimmune hepatitis in childhood: a 20-year experience. *Hepatology* 1997; **25**: 541-547 [PMID: 9049195 DOI: 10.1002/hep.510250308]

32 **Deneau MR**, El-Matary W, Valentino PL, Abdou R, Alqoaer K, Amin M, Amir AZ, Auth M, Bazerbachi F, Broderick A, Chan A, Cotter J, Doan S, El-Youssef M, Ferrari F, Furuya KN, Gottrand M, Gottrand F, Gupta N, Homan M, Kamath BM, Kim KM, Kolho KL, Konidari A, Koot B, Iorio R, Ledder O, Mack C, Martinez M, Miloh T, Mohan P, O'Cathain N, Papadopoulou A, Ricciuto A, Saubermann L, Sathya P, Shteyer E, Smolka V, Tanaka A, Varier R, Venkat V, Vitola B, Vos MB, Woynarowski M, Yap J, Jensen MK. The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration. *Hepatology* 2017; **66**: 518-527 [PMID: 28390159 DOI: 10.1002/hep.29204]

33 **Davit-Spraul A**, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, Bernard O, Jacquemin E. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. *Hepatology* 2010; **51**: 1645-1655 [PMID: 20232290 DOI: 10.1002/hep.23539]

34 **Davit-Spraul A**, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. *Semin Liver Dis* 2010; **30**: 134-146 [PMID: 20422496 DOI: 10.1055/s-0030-1253223]

35 **Nayagam JS**, Williamson C, Joshi D, Thompson RJ. Review article: liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1. *Aliment Pharmacol Ther* 2020; **52**: 1628-1639 [PMID: 33070363 DOI: 10.1111/apt.16118]

36 **Rastogi A**, Krishnani N, Pandey R. Dubin-Johnson syndrome--a clinicopathologic study of twenty cases. *Indian J Pathol Microbiol* 2006; **49**: 500-504 [PMID: 17183837]

37 **Kamal S**, Abdelhakam S, Ghoraba D, Massoud Y, Aziz KA, Hassan H, Hafez T, Abdel Sallam A. The frequency, clinical course, and health related quality of life in adults with Gilbert's syndrome: a longitudinal study. *BMC Gastroenterol* 2019; **19**: 22 [PMID: 30717703 DOI: 10.1186/s12876-019-0931-2]

38 **Yachha SK**, Goel A, Khanna V, Poddar U, Srivastava A, Singh U. Ascitic form of sporadic acute viral hepatitis in children: a distinct entity for recognition. *J Pediatr Gastroenterol Nutr* 2010; **50**: 184-187 [PMID: 19966578 DOI: 10.1097/MPG.0b013e3181aecb4c]

39 **Valla D**, Flejou JF, Lebrec D, Bernuau J, Rueff B, Salzmann JL, Benhamou JP. Portal hypertension and ascites in acute hepatitis: clinical, hemodynamic and histological correlations. *Hepatology* 1989; **10**: 482-487 [PMID: 2777210 DOI: 10.1002/hep.1840100414]

40 **Dhole SD**, Kher AS, Ghildiyal RG, Tambse MP. Chronic Liver Diseases in Children: Clinical Profile and Histology. *J Clin Diagn Res* 2015; **9**: SC04-SC07 [PMID: 26393179 DOI: 10.7860/JCDR/2015/13383.6250]

41 **Bolia R**, Srivastava A, Yachha SK, Poddar U. Pediatric CLIF-SOFA score is the best predictor of 28-day mortality in children with decompensated chronic liver disease. *J Hepatol* 2018; **68**: 449-455 [PMID: 29024698 DOI: 10.1016/j.jhep.2017.10.001]

42 **Srivastava A**, Malik R, Bolia R, Yachha SK, Poddar U. Prevalence, Clinical Profile, and Outcome of Ascitic Fluid Infection in Children With Liver Disease. *J Pediatr Gastroenterol Nutr* 2017; **64**: 194-199 [PMID: 27482766 DOI: 10.1097/MPG.0000000000001348]

43 **Sarin SK**, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). *Hepatol Int* 2009; **3**: 269-282 [PMID: 19669378 DOI: 10.1007/s12072-008-9106-x]

44 **Alam S**, Lal BB, Sood V, Rawat D. Pediatric Acute-on-Chronic Liver Failure in a Specialized Liver Unit: Prevalence, Profile, Outcome, and Predictive Factors. *J Pediatr Gastroenterol Nutr* 2016; **63**: 400-405 [PMID: 26967824 DOI: 10.1097/MPG.0000000000001179]

45 **Runyon BA**; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009; **49**: 2087-2107 [PMID: 19475696 DOI: 10.1002/hep.22853]

46 **O'Grady JG**, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. *Lancet* 1993; **342**: 273-275 [PMID: 8101303 DOI: 10.1016/0140-6736(93)91818-7]

47 **Bernuau J**, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. *Semin Liver Dis* 1986; **6**: 97-106 [PMID: 3529410 DOI: 10.1055/s-2008-1040593]

48 **Gimson AE**, O'Grady J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure: clinical, serological and histological features. *Hepatology* 1986; **6**: 288-294 [PMID: 3082735 DOI: 10.1002/hep.1840060222]

49 **Bernal W**, Auzinger G, Dhawan A, Wendon J. Acute liver failure. *Lancet* 2010; **376**: 190-201 [PMID: 20638564 DOI: 10.1016/S0140-6736(10)60274-7]

50 **Squires RH Jr**, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, Rosenthal P, Rodriguez-Baez N, Murray KF, Horslen S, Martin MG, Lopez MJ, Soriano H, McGuire BM, Jonas MM, Yazigi N, Shepherd RW, Schwarz K, Lobritto S, Thomas DW, Lavine JE, Karpen S, Ng V, Kelly D, Simonds N, Hynan LS. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. *J Pediatr* 2006; **148**: 652-658 [PMID: 16737880 DOI: 10.1016/j.jpeds.2005.12.051]

51 **Oketani M**, Ido A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, Ichida T, Mochida S, Onishi S, Tsubouchi H; Intractable Hepato-Biliary Diseases Study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009. *Hepatol Res* 2013; **43**: 97-105 [PMID: 23409848 DOI: 10.1111/j.1872-034X.2012.01105.x]

52 **Kumar A**, Yachha SK, Poddar U, Singh U, Aggarwal R. Does co-infection with multiple viruses adversely influence the course and outcome of sporadic acute viral hepatitis in children? *J Gastroenterol Hepatol* 2006; **21**: 1533-1537 [PMID: 16928213 DOI: 10.1111/j.1440-1746.2006.04509.x]

53 **Tandon ON,** Joshi YK, Acharya SK. Subacute hepatic failure. *Natl Med J India* 1988; **1**: 124-127

54 **Singh SK**, Sen Sarma M, Yachha SK, Srivastava A, Poddar U. Late-Onset Hepatic Failure in Children: Risk Factors that Determine the Outcome. *Dig Dis* 2020; **38**: 415-420 [PMID: 31940614 DOI: 10.1159/000505124]

55 **European Association for the Study of the Liver**. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

56 **Sharma D**, Singh O, Juneja D, Goel A, Garg SK, Shekhar S. Hepatitis A Virus-induced Severe Hemolysis Complicated by Severe Glucose-6-Phosphate Dehydrogenase Deficiency. *Indian J Crit Care Med* 2018; **22**: 670-673 [PMID: 30294135 DOI: 10.4103/ijccm.IJCCM\_260\_18]

57 **Walshe JM**. The acute haemolytic syndrome in Wilson's disease--a review of 22 patients. *QJM* 2013; **106**: 1003-1008 [PMID: 23842488 DOI: 10.1093/qjmed/hct137]

58 **Das MC**, Sen Sarma M, Srivastava A, Yachha SK, Poddar U. Effect of chelation therapy in pediatric Wilson's disease: Liver and endoscopic outcome. *J Hepatobiliary Pancreat Sci* 2021; **28**: 336-345 [PMID: 32745371 DOI: 10.1002/jhbp.812]

59 **Ferenci P**, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F. Diagnosis and phenotypic classification of Wilson disease. *Liver Int* 2003; **23**: 139-142 [PMID: 12955875 DOI: 10.1034/j.1600-0676.2003.00824.x]

60 **Pham HP**, Schwartz J, Cooling L, Hofmann JC, Kim HC, Morgan S, Pagano MB, Schneiderman J, Winters JL, Yamada C, Wong EC, Wu Y. Report of the ASFA apheresis registry study on Wilson's disease. *J Clin Apher* 2016; **31**: 11-15 [PMID: 26275240 DOI: 10.1002/jca.21396]

61 **Sood V**, Lal BB, Rawat D, Khanna R, Rastogi A, Bihari C, Kumar G, Alam S. Spectrum of Pediatric Autoimmune Liver Disease and Validation of Its Diagnostic Scores in Indian Children. *J Pediatr Gastroenterol Nutr* 2018; **67**: e65-e72 [PMID: 29901555 DOI: 10.1097/MPG.0000000000002050]

62 **Doshi BS**, Kamdar A, Lambert MP, Obstfeld AE. Hemolysis After Medication Exposure in Pediatric Patients With G6PD Deficiency. *J Pediatr Hematol Oncol* 2021 [PMID: 34654762 DOI: 10.1097/MPH.0000000000002350]

63 **Abdel-Ghaffar TY**, Sira MM, Sira AM, Salem TA, El-Sharawy AA, El Naghi S. Serological markers of autoimmunity in children with hepatitis A: relation to acute and fulminant presentation. *Eur J Gastroenterol Hepatol* 2015; **27**: 1161-1169 [PMID: 26062080 DOI: 10.1097/MEG.0000000000000413]

64 **Tabak F**, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. *Ann Hepatol* 2008; **7**: 177-179 [PMID: 18626439 DOI: 10.1016/S1665-2681(19)31878-2]

65 **Webb GW**, Dalton HR. Hepatitis E: an expanding epidemic with a range of complications. *Clin Microbiol Infect* 2020; **26**: 828-832 [PMID: 32251845 DOI: 10.1016/j.cmi.2020.03.039]

**Footnotes**

**Conflict-of-interest statement:** Both authors have no conflicts of interests to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 6, 2022

**First decision:** February 8, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Halawi A, Saudi Arabia; Zhou L, China **S-Editor:** Wang LL **L-Editor:** Kerr C **P-Editor:** Wang LL


**Figure Legends**




**Figure 1 Spectrum of acute viral hepatitis.**

****


**Figure 2 Overlapping atypical manifestations of acute viral hepatitis.** CLD: Chronic liver disease; DILI: Drug-induced liver injury.

****


**Figure 3 Natural history of classical acute viral hepatitis.** LFT: Liver function tests.

****


**Figure 4 Natural history of prolonged cholestasis in acute viral hepatitis.** LFT: Liver function tests; UDCA: Ursodeoxycholic acid; ALT: Alanine aminotransferase; TB/DB: Tuberculosis/Disulfide bond; ALP: Alkaline phosphatase; INR: International normalized ratio.

****

**Figure 5 Natural history of relapsing hepatitis in acute viral hepatitis.** CLD: Chronic liver disease; ALT: Alanine aminotransferase; LFT: Liver function tests.

****

**Figure 6 Natural history of ascites in acute viral hepatitis.** LVP: Levator veli palatine; SAAG: Serum-ascites albumin gradient; SBP: Systolic blood pressure; CLD: Chronic liver disease; LFT: Liver function tests.

****

**Figure 7 Natural history of intravascular hemolysis (G6PD deficiency) in acute viral hepatitis.** LDH: Lactate dehydrogenase; TB: Tuberculosis; IB: Illipe butter; DB: Disulfide bond; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; PRBC: Packed red blood cells; LFT: Liver function tests.

**Table 1 Differentiation between Ascitic form of acute viral hepatitis, decompensated chronic liver disease, acute on chronic liver failure and late onset hepatic failure**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Ascitic form of AVH[26]** | **Decompensated CLD[29]** | **ACLF[31]** | **LOHF[42]** |
| Prodrome | Yes | No | Yes/No | Yes |
| Jaundice to ascites interval | Variable | Within first 3-4 wk | Within first 3-4 wk | After 3-4 wk |
| Encephalopathy | No | 43% | 66% | 51% |
| Coagulopathy | No | Yes | Yes | Yes |
| Variceal bleeding | No | 16% | 14% | No |
| Growth failure | No | Yes | 28% | No |
| Stigmata of liver disease | No | Yes | Yes | No |
| Acute insult | Yes | No | Yes | Yes |
| Nature of ascites | Rapidly resolving and  Non-recurrent | Intractable and recurrent | Intractable and recurrent | Intractable and recurrent |
| Liver span | Enlarged | Enlarged or shrunken | Enlarged or shrunken | Mostly shrunken |
| Liver nodularity | No | Yes | Yes | No |
| Liver margins | Regular | Irregular | Irregular | Regular |
| Portal vein | Normal | May be dilated | May be dilated | Normal |
| Large Esophageal varices | No | May be present | May be present | No |
| Gastric varices | No | Yes | Yes | No |
| Survival with native liver | Yes | 66% | 61% | 25% |

AVH: Acute viral hepatitis; CLD: Chronic liver disease; ACLF: Acute on chronic liver failure; LOHF: Late onset hepatic failure.